Alastair Wilkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alastair Wilkins has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Neil Scolding
Department of Internal Medicine, Gulu Medical School, Gulu University , Gulu , Uganda
6 shared publications - Claire M. Rice
Institute of Clinical Neurosciences, University of Bristol, Bristol, UK
3 shared publications Kelly Hares
Institute of Clinical Neurosciences, University of Bristol, Southmead Hospital, Bristol, Bristol, UK BS 10 5NB
3 shared publications- Kevin Kemp
University of Bristol
3 shared publications - Elizabeth Gray
MS Labs, Burden Centre, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, UK
2 shared publications - Chris Metcalfe
Population Health Sciences, University of Bristol, Bristol, UK
1 shared publication
Latest Publications
- Open Access
- 25 November 2017
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 19 (12) , 47
Treatment of Cerebellar Ataxia in the Context of Systemic Diseases
Purpose of review The purpose of this review is to assess the evidence behind treatment regimens for cerebellar ataxias occurring in the context of systemic disease. We will address systemic conditions which are associated with specific involvement of the cerebellum (rather than widespread nervous system involvement) and those conditions for which some degree of evidence of treatment response exists. Recent findings We have divided systemic disorders affecting the cerebellum into systemic immunological disorders, endocrine and metabolic disorders and paraneoplastic. Recent studies have increased understanding of the range of cerebellar disorders associated with a systemic immunological condition. The identification of newer pathogenic antibodies has improved diagnosis in conditions which would have previously been labelled as idiopathic. However, their rarity and phenotypic variability makes defining optimal immunomodulatory treatment regimens challenging. There is some evidence for beneficial effects of immunomodulation, particularly in anti-GAD ataxia and Hashimoto’s encephalopathy, although, at this time, specific treatment regimens cannot be defined. Immune-mediated paraneoplastic cerebellar disorders show response to therapy dependent, to some extent, on the underlying pathogenic antibody. Much is still to be understood concerning treatment regimens for the ataxic manifestations of metabolic disorders, notably alcohol-induced cerebellar injury, which are common and which are associated with significant disability. Summary Despite their rarity, cerebellar ataxias occurring in the context of systemic disease cause significant morbidity and better therapies are required to improve outcomes associated with these conditions.
- 25 November 2017
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 19 (12) , 47
Open AccessTreatment of Cerebellar Ataxia in the Context of Systemic Diseases
Purpose of review The purpose of this review is to assess the evidence behind treatment regimens for cerebellar ataxias occurring in the context of systemic disease. We will address systemic conditions which are associated with specific involvement of the cerebellum (rather than widespread nervous system involvement) and those conditions for which some degree of evidence of treatment response exists. Recent findings We have divided systemic disorders affecting the cerebellum into systemic immunological disorders, endocrine and metabolic disorders and paraneoplastic. Recent studies have increased understanding of the range of cerebellar disorders associated with a systemic immunological condition. The identification of newer pathogenic antibodies has improved diagnosis in conditions which would have previously been labelled as idiopathic. However, their rarity and phenotypic variability makes defining optimal immunomodulatory treatment regimens challenging. There is some evidence for beneficial effects of immunomodulation, particularly in anti-GAD ataxia and Hashimoto’s encephalopathy, although, at this time, specific treatment regimens cannot be defined. Immune-mediated paraneoplastic cerebellar disorders show response to therapy dependent, to some extent, on the underlying pathogenic antibody. Much is still to be understood concerning treatment regimens for the ataxic manifestations of metabolic disorders, notably alcohol-induced cerebellar injury, which are common and which are associated with significant disability. Summary Despite their rarity, cerebellar ataxias occurring in the context of systemic disease cause significant morbidity and better therapies are required to improve outcomes associated with these conditions.
- 3 August 2017
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 11 (8) , 589-591
Axonal Transport Proteins as Biomarkers of Neurodegeneration?
- 3 August 2017
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 11 (8) , 589-591
Axonal Transport Proteins as Biomarkers of Neurodegeneration?
- Open Access
- 28 June 2017
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 8, 312
Cerebellar Dysfunction in Multiple Sclerosis
Multiple sclerosis (MS) commonly affects the cerebellum causing acute and chronic symptoms. Cerebellar signs contribute significantly to clinical disability, and symptoms such as tremor, ataxia and dysarthria are particularly difficult to treat. Increasing knowledge concerning the pathophysiology of cerebellar disease in MS from human post mortem studies, experimental models and clinical trials has raised the hope that cerebellar symptoms will be better treated in the future.
- 28 June 2017
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 8, 312
Open AccessCerebellar Dysfunction in Multiple Sclerosis
Multiple sclerosis (MS) commonly affects the cerebellum causing acute and chronic symptoms. Cerebellar signs contribute significantly to clinical disability, and symptoms such as tremor, ataxia and dysarthria are particularly difficult to treat. Increasing knowledge concerning the pathophysiology of cerebellar disease in MS from human post mortem studies, experimental models and clinical trials has raised the hope that cerebellar symptoms will be better treated in the future.
- Open Access
- 14 October 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-8
Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
We have recently completed an evaluation of the safety and feasibility of intravenous delivery of autologous bone marrow in patients with progressive multiple sclerosis (MS). The possibility of repair was suggested by improvement in the neurophysiological secondary outcome measure seen in all participants. The current study will examine the efficacy of intravenous delivery of autologous marrow in progressive MS. Laboratory studies performed in parallel with the clinical trial will further investigate the biology of bone marrow-derived stem cell infusion in MS, including mechanisms underlying repair. A prospective, randomised, double-blind, placebo-controlled, stepped wedge design will be employed at a single centre (Bristol, UK). Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS). Participants will be randomised to either early or late (1 year) intravenous infusion of autologous, unfractionated bone marrow. The placebo intervention is infusion of autologous blood. The primary outcome measure is global evoked potential derived from multimodal evoked potentials. Secondary outcome measures include adverse event reporting, clinical (EDSS and MSFC) and self-assessment (MSIS-29) rating scales, optical coherence tomography (OCT) as well as brain and spine MRI. Participants will be followed up for a further year following the final intervention. Outcomes will be analysed on an intention-to-treat basis. Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS) is the first randomised, placebo-controlled trial of non-myeloablative autologous bone marrow-derived stem cell therapy in MS. It will determine whether bone marrow cell therapy can, as was suggested by the phase I safety study, improve conduction in multiple central nervous system pathways affected in progressive MS. Furthermore, laboratory studies performed in parallel with the clinical trial will inform our understanding of the cellular pharmacodynamics of bone marrow infusion in MS patients and the mechanisms underlying cell therapy. ISRCTN27232902 Registration date 11/09/2012. NCT01815632 Registration date 19/03/2013
- 14 October 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-8
Open AccessAssessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
We have recently completed an evaluation of the safety and feasibility of intravenous delivery of autologous bone marrow in patients with progressive multiple sclerosis (MS). The possibility of repair was suggested by improvement in the neurophysiological secondary outcome measure seen in all participants. The current study will examine the efficacy of intravenous delivery of autologous marrow in progressive MS. Laboratory studies performed in parallel with the clinical trial will further investigate the biology of bone marrow-derived stem cell infusion in MS, including mechanisms underlying repair. A prospective, randomised, double-blind, placebo-controlled, stepped wedge design will be employed at a single centre (Bristol, UK). Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS). Participants will be randomised to either early or late (1 year) intravenous infusion of autologous, unfractionated bone marrow. The placebo intervention is infusion of autologous blood. The primary outcome measure is global evoked potential derived from multimodal evoked potentials. Secondary outcome measures include adverse event reporting, clinical (EDSS and MSFC) and self-assessment (MSIS-29) rating scales, optical coherence tomography (OCT) as well as brain and spine MRI. Participants will be followed up for a further year following the final intervention. Outcomes will be analysed on an intention-to-treat basis. Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS) is the first randomised, placebo-controlled trial of non-myeloablative autologous bone marrow-derived stem cell therapy in MS. It will determine whether bone marrow cell therapy can, as was suggested by the phase I safety study, improve conduction in multiple central nervous system pathways affected in progressive MS. Furthermore, laboratory studies performed in parallel with the clinical trial will inform our understanding of the cellular pharmacodynamics of bone marrow infusion in MS patients and the mechanisms underlying cell therapy. ISRCTN27232902 Registration date 11/09/2012. NCT01815632 Registration date 19/03/2013
- 1 August 2014
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (9) , 1828-1829
Thyroid papillary carcinoma after alemtuzumab therapy for MS
- 1 August 2014
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (9) , 1828-1829
Thyroid papillary carcinoma after alemtuzumab therapy for MS
- 1 April 2014
- Published by Elsevier in Brain Research
- Vol. 1559, 55-64
Increased microglial catalase activity in multiple sclerosis grey matter
- 1 April 2014
- Published by Elsevier in Brain Research
- Vol. 1559, 55-64
Increased microglial catalase activity in multiple sclerosis grey matter
- 12 December 2012
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (12) , 1682-1683
The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: No
- 12 December 2012
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (12) , 1682-1683
The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: No
- 29 June 2012
- Published by Springer Nature
- p. 147-186
Symptomatic Treatment for Progressive Multiple Sclerosis
- 29 June 2012
- Published by Springer Nature
- p. 147-186
Symptomatic Treatment for Progressive Multiple Sclerosis
- 29 June 2012
- Published by Springer Nature
- p. 11-30
What Is Disease Progression?
- 29 June 2012
- Published by Springer Nature
- p. 1-9
General Introduction